Appointment of W. Mark Watson
SOUTH SAN FRANCISCO, Calif. — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company, proudly announces the appointment of W. Mark Watson as its Lead Independent Director. With a wealth of knowledge spanning over 50 years in the field of accounting and business, Mr. Watson is set to significantly enhance the strategic direction of the company.
Background of W. Mark Watson
Mr. Watson is a Certified Public Accountant, having invested more than four decades at Deloitte Touche Tohmatsu, where he honed his expertise in financial oversight and corporate governance. His extensive career also includes pivotal roles on the boards of various biotech companies, where he has served with distinction. Since joining Vaxart's Board in August 2022, Mr. Watson has brought invaluable insights and leadership to the organization.
Previous Roles and Experience
Throughout his career, Mr. Watson has held multiple positions, including Chairman of the Board and Audit Committee at Inhibitor Therapeutics, Inc. and Director at Sykes Enterprises, Inc. His advisory role at BioDelivery Sciences International, Inc. has further solidified his reputation as a seasoned leader within the biotech community.
Commitment to Vaxart's Mission
Expressing his enthusiasm for the new role, Mr. Watson stated, "I am excited to take on this role and fully support our leadership team in their mission to advance the Company's groundbreaking oral vaccine platform. We believe strongly in the direction Vaxart is heading and its potential to transform global public health." His commitment reflects a wider determination within the company to engage transparently with shareholders and stakeholders alike.
Enhancing Shareholder Engagement
In addition to Mr. Watson's leadership, Vaxart is working to implement a stock ownership policy among its Board of Directors. This initiative aims to align the interests of the Board more closely with those of Vaxart’s shareholders, thereby reinforcing the company's dedication to corporate governance and accountability.
Ongoing Shareholder Communication
Vaxart's leadership team has prioritized open communication with investors. They have held multiple quarterly conference calls and initiated a fireside chat series to ensure clarity in their strategies and operations. This proactive approach demonstrates Vaxart’s commitment to keeping shareholders informed and engaged.
Special Meeting of Stockholders
A special meeting for stockholders is set for September 19, 2025, at 8:30 a.m. Pacific Time. This meeting will take place virtually, providing stockholders with the opportunity to participate regardless of location. Vaxart continues to encourage stockholders of record who haven't cast their votes to do so before the deadline.
Voting Details
Those eligible to vote must do so by 11:59 p.m. Eastern Time on September 18, 2025. The company emphasizes that even stockholders who previously voted against the reverse stock split proposal can change their vote in favor of the initiative. This shift highlights Vaxart's adaptability and responsiveness to shareholder sentiments.
About Vaxart
Vaxart is redefining the way vaccines are delivered by developing oral recombinant vaccines that can be produced without refrigeration. These innovations aim to mitigate the risk associated with traditional needle-based vaccines and make immunizations more accessible. The company is actively pursuing vaccines for various diseases, including COVID-19, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV). Vaxart has robust patent applications to protect its unique delivery technology and product developments.
Contact Information
For any questions or further assistance regarding voting, stockholders can reach out to Vaxart's proxy solicitation firm at:
Campaign Management, LLC
Toll-Free: 1-855-264-1527
Email: info@campaign-mgmt.com
Frequently Asked Questions
Who has been appointed as the Lead Independent Director of Vaxart?
W. Mark Watson has been appointed as the Lead Independent Director of Vaxart.
What experience does W. Mark Watson bring to Vaxart?
Mr. Watson has over 50 years of experience, including significant time spent at Deloitte and various roles on biotech boards.
What is Vaxart's mission?
Vaxart aims to innovate vaccine delivery through oral recombinant vaccines, making them more accessible and safer.
When will the special meeting of stockholders take place?
The meeting is scheduled for September 19, 2025, at 8:30 a.m. Pacific Time.
How can stockholders participate in the voting process?
Eligible stockholders can cast their votes virtually on the specified date by utilizing their control numbers provided in proxy materials.
